Trial Outcomes & Findings for Redirected Auto T Cells for Advanced Myeloma (NCT NCT01352286)
NCT ID: NCT01352286
Last Updated: 2019-12-03
Results Overview
Number of Participants with Adverse Events related to study treatment
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
25 participants
Primary outcome timeframe
Day -40 to Year 1 post-treatment
Results posted on
2019-12-03
Participant Flow
Participant milestones
| Measure |
NYESO-1ᶜ²⁵⁹T Cells Administered Intravenously
Participants who received lentivirus-mediated genetically engineered NYESO-1ᶜ²⁵⁹T following autologous stem cell transplantation (ASCT)
|
|---|---|
|
Overall Study
STARTED
|
25
|
|
Overall Study
Received T-cells
|
25
|
|
Overall Study
COMPLETED
|
25
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Redirected Auto T Cells for Advanced Myeloma
Baseline characteristics by cohort
| Measure |
NYESO-1ᶜ²⁵⁹T Cells
n=25 Participants
Participants who received NYESO-1ᶜ²⁵⁹T following ASCT
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
17 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
8 Participants
n=5 Participants
|
|
Age, Continuous
|
59 years
n=5 Participants
|
|
Sex: Female, Male
Female
|
10 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
15 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
25 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
5 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
19 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
1 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: Day -40 to Year 1 post-treatmentPopulation: Participants who received NYESO-1ᶜ²⁵⁹T following ASCT
Number of Participants with Adverse Events related to study treatment
Outcome measures
| Measure |
NYESO-1ᶜ²⁵⁹T Cells
n=25 Participants
Participants who received NYESO-1ᶜ²⁵⁹T following ASCT
|
|---|---|
|
Adverse Events Related to Study Treatment
|
24 participants
|
SECONDARY outcome
Timeframe: Change from Baseline at Day 42, 100, 180, 270 and Year 1Population: Participants who received NYESO-1ᶜ²⁵⁹T following ASCT
Objective Response Rate (ORR) of sCR (stringent complete response), CR (complete response), VGPR (very good partial response), PR (partial response)
Outcome measures
| Measure |
NYESO-1ᶜ²⁵⁹T Cells
n=25 Participants
Participants who received NYESO-1ᶜ²⁵⁹T following ASCT
|
|---|---|
|
Number of Participants With Response Per International Myeloma Working Group (IMWG) 2011 Criteria
Day 42
|
20 Participants
|
|
Number of Participants With Response Per International Myeloma Working Group (IMWG) 2011 Criteria
Day 100
|
19 Participants
|
|
Number of Participants With Response Per International Myeloma Working Group (IMWG) 2011 Criteria
Day 180
|
16 Participants
|
|
Number of Participants With Response Per International Myeloma Working Group (IMWG) 2011 Criteria
Day 270
|
13 Participants
|
|
Number of Participants With Response Per International Myeloma Working Group (IMWG) 2011 Criteria
Year 1
|
11 Participants
|
SECONDARY outcome
Timeframe: Best Objective Response prior to initiation of lenalidomide and at Year 1Population: Participants who received NYESO-1ᶜ²⁵⁹T following ASCT with Best Objective Response (BOR) data.
Number of participants with Best Objective Response of sCR, CR, VGPR, or PR
Outcome measures
| Measure |
NYESO-1ᶜ²⁵⁹T Cells
n=25 Participants
Participants who received NYESO-1ᶜ²⁵⁹T following ASCT
|
|---|---|
|
Best Objective Response (BOR)
Prior to Initiation of Lenalidomide : sCR
|
1 Participants
|
|
Best Objective Response (BOR)
Prior to Initiation of Lenalidomide : CR
|
0 Participants
|
|
Best Objective Response (BOR)
Prior to Initiation of Lenalidomide : VGPR
|
12 Participants
|
|
Best Objective Response (BOR)
Prior to Initiation of Lenalidomide : PR
|
7 Participants
|
|
Best Objective Response (BOR)
Year 1 : sCR
|
2 Participants
|
|
Best Objective Response (BOR)
Year 1 : CR
|
1 Participants
|
|
Best Objective Response (BOR)
Year 1 : VGPR
|
13 Participants
|
|
Best Objective Response (BOR)
Year 1 : PR
|
5 Participants
|
SECONDARY outcome
Timeframe: DOR: Initial date of response to date of progressive disease or death PFS: Date of first T -cell infusion to earliest date of disease progression of death due to any cause OS: Date of first T-cell infusion to date of death from any cause.Population: Participants who received NYESO-1ᶜ²⁵⁹T following ASCT
Calculated median DOR, PFS, OS
Outcome measures
| Measure |
NYESO-1ᶜ²⁵⁹T Cells
n=25 Participants
Participants who received NYESO-1ᶜ²⁵⁹T following ASCT
|
|---|---|
|
Duration of Response (DOR), Progression Free Survival (PFS), Overall Survival (OS)
PFS
|
13.5 median months
Interval 8.9 to 31.1
|
|
Duration of Response (DOR), Progression Free Survival (PFS), Overall Survival (OS)
DOR
|
12.2 median months
Interval 7.6 to 29.8
|
|
Duration of Response (DOR), Progression Free Survival (PFS), Overall Survival (OS)
OS
|
35.1 median months
Interval 22.7 to
The 95% upper confidence limits for median overall survival could not be calculated because of the high number/proportion (11 participants/44%) of participants alive at the time of the analysis.
|
SECONDARY outcome
Timeframe: Post-infusion through Day 42Population: Participants who received NYESO-1ᶜ²⁵⁹T following ASCT
Measurement of NY-ESO-1ᶜ²⁵⁹T cells in blood
Outcome measures
| Measure |
NYESO-1ᶜ²⁵⁹T Cells
n=25 Participants
Participants who received NYESO-1ᶜ²⁵⁹T following ASCT
|
|---|---|
|
Peak Persistence of Modified T-cells in the Peripheral Blood
|
143728.793 copies per μg of DNA
Interval 7560.1 to 284312.37
|
SECONDARY outcome
Timeframe: Pre- and post-infusionPopulation: Participants who received NYESO-1ᶜ²⁵⁹T following ASCT with expression data at all points.
Number of participants with NY-ESO-1 and LAGE or LAGE-1a expression in the marrow post-infusion
Outcome measures
| Measure |
NYESO-1ᶜ²⁵⁹T Cells
n=25 Participants
Participants who received NYESO-1ᶜ²⁵⁹T following ASCT
|
|---|---|
|
Marrow Antigen Expression Pre-and Post-infusion
Day 100 : LAGE or LAGE-1a
|
16 participants
|
|
Marrow Antigen Expression Pre-and Post-infusion
Day 180 : NY-ESO-1
|
14 participants
|
|
Marrow Antigen Expression Pre-and Post-infusion
Day 180 : LAGE or LAGE-1a
|
14 participants
|
|
Marrow Antigen Expression Pre-and Post-infusion
Day 100 : NY-ESO-1
|
16 participants
|
SECONDARY outcome
Timeframe: Post TreatmentPopulation: Participants who received NYESO-1ᶜ²⁵⁹T following ASCT with engraftment data.
Number of participants with engraftment in blood and bone marrow
Outcome measures
| Measure |
NYESO-1ᶜ²⁵⁹T Cells
n=25 Participants
Participants who received NYESO-1ᶜ²⁵⁹T following ASCT
|
|---|---|
|
Engraftment of Gene-modified Pentamer+ CD4+ T Cells and CD8+ T Cells
CD4+ : Blood
|
11 participants
|
|
Engraftment of Gene-modified Pentamer+ CD4+ T Cells and CD8+ T Cells
CD4+ : Bone Marrow
|
11 participants
|
|
Engraftment of Gene-modified Pentamer+ CD4+ T Cells and CD8+ T Cells
CD8+ : Blood
|
11 participants
|
|
Engraftment of Gene-modified Pentamer+ CD4+ T Cells and CD8+ T Cells
CD8+ : Bone Marrow
|
11 participants
|
Adverse Events
NYESO-1ᶜ²⁵⁹T Cells
Serious events: 17 serious events
Other events: 25 other events
Deaths: 14 deaths
Serious adverse events
| Measure |
NYESO-1ᶜ²⁵⁹T Cells
n=25 participants at risk
Participants who received NYESO-1ᶜ²⁵⁹T following ASCT
|
|---|---|
|
Investigations
Myoglobin blood
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Cardiac disorders
Atrial fibrillation
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Blood and lymphatic system disorders
Neutropenia
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
General disorders
Pyrexia
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Immune system disorders
Graft versus host disease
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Gastrointestinal disorders
Hypoxia
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Infections and infestations
Staphylococcal infection
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Renal and urinary disorders
Acute Kidney Injury
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
General disorders
Asthenia
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Immune system disorders
Autoimmune disorder
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Investigations
Blood creatine phosphokinase increased
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Investigations
Blood lactate dehydrogenase increased
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Gastrointestinal disorders
Colitis
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Vascular disorders
Deep vein thrombosis
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Metabolism and nutrition disorders
Dehydration
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Investigations
Ejection Fraction
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Metabolism and nutrition disorders
Failure to Thrive
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Gastrointestinal disorders
Graft versus host disease in gastrointestinal tract
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Injury, poisoning and procedural complications
Hip Fracture
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Infections and infestations
Hepatic infection
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Renal and urinary disorders
Hydronephrosis
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Vascular disorders
Hypotension
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Infections and infestations
Influenza
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Infections and infestations
Klebsiella infection
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Blood and lymphatic system disorders
Leukopenia
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Investigations
Myoglobin urine
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Infections and infestations
Neutropenic sepsis
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Investigations
Neutrophil count decreased
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Plasmacytoma
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Investigations
Platelet count decreased
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary edema
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Musculoskeletal and connective tissue disorders
Rhabdomyolysis
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Nervous system disorders
Syncope
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Infections and infestations
Viral upper respiratory tract infection
|
4.0%
1/25 • Number of events 1 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
Other adverse events
| Measure |
NYESO-1ᶜ²⁵⁹T Cells
n=25 participants at risk
Participants who received NYESO-1ᶜ²⁵⁹T following ASCT
|
|---|---|
|
Gastrointestinal disorders
Nausea
|
100.0%
25/25 • Number of events 25 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Blood and lymphatic system disorders
Anaemia
|
96.0%
24/25 • Number of events 24 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Gastrointestinal disorders
Diarrhea
|
96.0%
24/25 • Number of events 24 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Metabolism and nutrition disorders
Decreased appetite
|
92.0%
23/25 • Number of events 23 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
72.0%
18/25 • Number of events 18 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Investigations
Platelet count decreased
|
48.0%
12/25 • Number of events 12 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
General disorders
Fatigue
|
88.0%
22/25 • Number of events 22 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
80.0%
20/25 • Number of events 20 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Skin and subcutaneous tissue disorders
Erythema multiforme
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
General disorders
Pyrexia
|
80.0%
20/25 • Number of events 20 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Metabolism and nutrition disorders
Hypokalemia
|
76.0%
19/25 • Number of events 19 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Gastrointestinal disorders
Vomiting
|
76.0%
19/25 • Number of events 19 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
64.0%
16/25 • Number of events 16 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
60.0%
15/25 • Number of events 15 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Blood and lymphatic system disorders
Leukopenia
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Investigations
WBC decreased
|
52.0%
13/25 • Number of events 13 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Blood and lymphatic system disorders
Neutropenia
|
32.0%
8/25 • Number of events 8 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Investigations
Neutrophil count decreased
|
32.0%
8/25 • Number of events 8 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
56.0%
14/25 • Number of events 14 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
56.0%
14/25 • Number of events 14 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
General disorders
Oedema peripheral
|
56.0%
14/25 • Number of events 14 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Gastrointestinal disorders
Stomatitis
|
56.0%
14/25 • Number of events 14 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Gastrointestinal disorders
Abdominal pain
|
52.0%
13/25 • Number of events 13 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
52.0%
13/25 • Number of events 13 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Gastrointestinal disorders
Constipation
|
48.0%
12/25 • Number of events 12 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Metabolism and nutrition disorders
Hyperglycemia
|
48.0%
12/25 • Number of events 12 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
48.0%
12/25 • Number of events 12 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Metabolism and nutrition disorders
Hypophosphataemia
|
48.0%
12/25 • Number of events 12 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
48.0%
12/25 • Number of events 12 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Nervous system disorders
Headache
|
44.0%
11/25 • Number of events 11 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Infections and infestations
Upper respiratory tract infection
|
44.0%
11/25 • Number of events 11 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
General disorders
Chills
|
40.0%
10/25 • Number of events 10 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Vascular disorders
Hypotension
|
36.0%
9/25 • Number of events 9 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
36.0%
9/25 • Number of events 9 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
32.0%
8/25 • Number of events 8 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Psychiatric disorders
Insomnia
|
32.0%
8/25 • Number of events 8 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
32.0%
8/25 • Number of events 8 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
28.0%
7/25 • Number of events 7 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Gastrointestinal disorders
Oral Pain
|
28.0%
7/25 • Number of events 7 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
General disorders
Pain
|
28.0%
7/25 • Number of events 7 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Investigations
Alanine aminotransferase increased
|
24.0%
6/25 • Number of events 6 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Psychiatric disorders
Anxiety
|
24.0%
6/25 • Number of events 6 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
24.0%
6/25 • Number of events 6 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Nervous system disorders
Dizziness
|
24.0%
6/25 • Number of events 6 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
24.0%
6/25 • Number of events 6 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Musculoskeletal and connective tissue disorders
Neck Pain
|
24.0%
6/25 • Number of events 6 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Cardiac disorders
Tachycardia
|
24.0%
6/25 • Number of events 6 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Investigations
Blood alkaline phosphatase increased
|
20.0%
5/25 • Number of events 5 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Infections and infestations
Candida infection
|
20.0%
5/25 • Number of events 5 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Immune system disorders
Graft Versus Host Disease (GVHD)
|
16.0%
4/25 • Number of events 4 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
General disorders
Localized edema
|
20.0%
5/25 • Number of events 5 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Investigations
Lymphocyte count decreased
|
20.0%
5/25 • Number of events 5 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
20.0%
5/25 • Number of events 5 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Cardiac disorders
Sinus tachycardia
|
20.0%
5/25 • Number of events 5 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Gastrointestinal disorders
Abdominal distension
|
16.0%
4/25 • Number of events 4 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
16.0%
4/25 • Number of events 4 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Investigations
Aspartate aminotransferase increased
|
16.0%
4/25 • Number of events 4 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Investigations
Blood creatinine increased
|
16.0%
4/25 • Number of events 4 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Psychiatric disorders
Depression
|
16.0%
4/25 • Number of events 4 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
16.0%
4/25 • Number of events 4 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Infections and infestations
Herpes zoster
|
16.0%
4/25 • Number of events 4 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Vascular disorders
Hypertension
|
16.0%
4/25 • Number of events 4 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Metabolism and nutrition disorders
Hypoglycemia
|
16.0%
4/25 • Number of events 4 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
General disorders
Mucosal inflammation
|
16.0%
4/25 • Number of events 4 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
16.0%
4/25 • Number of events 4 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Gastrointestinal disorders
Oesophagitis
|
16.0%
4/25 • Number of events 4 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Nervous system disorders
Paresthesia
|
16.0%
4/25 • Number of events 4 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
16.0%
4/25 • Number of events 4 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Investigations
Weight decreased
|
16.0%
4/25 • Number of events 4 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Renal and urinary disorders
Acute kidney injury
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Cardiac disorders
Atrial fibrillation
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Immune system disorders
Autoimmune disorder
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Investigations
Blood creatinine decreased
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
General disorders
Catheter site pain
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Infections and infestations
Clostridium difficile infection
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Psychiatric disorders
Confusional state
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Gastrointestinal disorders
Dry Mouth
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Nervous system disorders
Dysgeusia
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Respiratory, thoracic and mediastinal disorders
Hiccups
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Metabolism and nutrition disorders
Hypernatraemia
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
General disorders
Malaise
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Gastrointestinal disorders
Mouth ulceration
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Nervous system disorders
Neuralgia
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Gastrointestinal disorders
Neutropenic colitis
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Infections and infestations
Oral candidiasis
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Gastrointestinal disorders
Oral dysaesthesia
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Nervous system disorders
Peripheral motor neuropathy
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Infections and infestations
Pneumonia
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Respiratory, thoracic and mediastinal disorders
Rales
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Respiratory, thoracic and mediastinal disorders
Tachypnoea
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Nervous system disorders
Tremor
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
12.0%
3/25 • Number of events 3 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Gastrointestinal disorders
Abdominal tenderness
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Psychiatric disorders
Agitation
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Investigations
Blood bilirubin increased
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
General disorders
Catheter site discharge
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
General disorders
Catheter site hemorrhage
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
General disorders
Chest discomfort
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Infections and infestations
Clostridium difficile colitis
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Injury, poisoning and procedural complications
Contusion
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Metabolism and nutrition disorders
Dehydration
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Psychiatric disorders
Delirium
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Infections and infestations
Diverticulitis
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Gastrointestinal disorders
Dysphagia
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea exertional
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Skin and subcutaneous tissue disorders
Ecchymosis
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Skin and subcutaneous tissue disorders
Erythema
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
General disorders
Face edema
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Injury, poisoning and procedural complications
Fall
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Vascular disorders
Flushing
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Gastrointestinal disorders
Gastroesophageal reflux disease
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Renal and urinary disorders
Haematuria
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Metabolism and nutrition disorders
Hypermagnesaemia
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Investigations
International normalized ratio increased
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Musculoskeletal and connective tissue disorders
Joint range of motion decreased
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Metabolism and nutrition disorders
Malnutrition
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Nervous system disorders
Neuropathy peripheral
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Skin and subcutaneous tissue disorders
Palmar-plantar erythrodysaesthesia syndrome
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Cardiac disorders
Palpitations
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
General disorders
Peripheral swelling
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Skin and subcutaneous tissue disorders
Petechiae
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Plasmacytoma
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Skin and subcutaneous tissue disorders
Purpura
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Renal and urinary disorders
Renal failure
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Skin and subcutaneous tissue disorders
Scab
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Nervous system disorders
Sinus headache
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Respiratory, thoracic and mediastinal disorders
Sinus pain
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Infections and infestations
Sinusitis
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Skin and subcutaneous tissue disorders
Skin disorder
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Skin and subcutaneous tissue disorders
Skin ulcer
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Infections and infestations
Staphylococcal infection
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Infections and infestations
Tooth abscess
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Infections and infestations
Tooth infection
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Renal and urinary disorders
Urinary incontinence
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Cardiac disorders
Ventricular tachycardia
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Infections and infestations
Viral upper respiratory tract infection
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
|
Eye disorders
Vision blurred
|
8.0%
2/25 • Number of events 2 • Day -40 to Year 1 post-treatment
Participants who received NY-ESO-1ᶜ²⁵⁹T following ASCT
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: GT60